New COVID Variant 2026: What You Need to Know About BA.3.2, Stratus, and Nimbus

As the world enters another respiratory virus season, health officials are closely monitoring several new COVID-19 variants circulating globally. While the days of pandemic-level disruptions have largely passed, the virus continues to evolve, with several emerging strains demanding attention from public health authorities in 2026.

Here’s everything you need to know about the new COVID variants circulating this year—including BA.3.2, Stratus (XFG), and Nimbus—and how to protect yourself.

The Current Landscape: Multiple Variants in Circulation

The SARS-CoV-2 virus continues to evolve, with several subvariants currently spreading across the United States and worldwide. According to the Centers for Disease Control and Prevention (CDC), three main variants are being tracked: BA.3.2, Stratus (XFG) , and Nimbus .

While these variants have demonstrated increased transmissibility and immune-evasion capabilities, early data suggests they are not associated with more severe illness compared to earlier Omicron strains . However, their ability to spread efficiently means more people may become infected, potentially leading to increased hospitalizations among vulnerable populations.

BA.3.2: The Highly Mutated Variant Under Close Watch

What Is BA.3.2?

BA.3.2 is a new lineage of SARS-CoV-2 that has raised concerns due to its significant genetic divergence. First identified in South Africa in November 2024, the variant carries approximately 70 to 75 mutations in its spike protein compared to the JN.1 and LP.8.1 variants—the antigens used in the current COVID-19 vaccines .

Global Spread

As of February 2026, BA.3.2 has been detected in at least 23 countries across multiple continents . The variant first appeared in the United States in June 2025 through traveler-based surveillance at San Francisco International Airport. By mid-March 2026, it had been found in:

• 29 patients across multiple states

• 260 wastewater samples from 29 states and Puerto Rico

• Multiple traveler nasal swabs and airplane sewage samples

Prevalence and Growth

While BA.3.2 has shown significant growth in some European countries—accounting for approximately 30% of sequenced variants in Denmark, Germany, and the Netherlands during late 2025—its prevalence in the U.S. remains relatively low at 0.55% of sequenced specimens as of March 2026 .

Immune Evasion Potential

Laboratory studies indicate that BA.3.2 evades antibodies more effectively than other circulating variants. The 2025–26 COVID-19 vaccine demonstrated the lowest antibody neutralization against BA.3.2 among seven variants tested .

However, experts emphasize that real-world vaccine effectiveness data is still needed. The CDC notes that current vaccines continue to protect against severe disease from predominant circulating strains .

Clinical Severity

Encouragingly, BA.3.2 does not appear to cause more severe illness. Among the five U.S. patients with confirmed BA.3.2 infections, two were hospitalized older adults with comorbidities—and all five survived . The variant also shows reduced lung cell entry compared to other variants, which may limit its ability to cause severe disease .

Stratus (XFG) and Nimbus: The Summer 2025 Variants

Stratus (XFG)

Stratus, formally known as XFG, is a recombinant variant formed from two earlier variants, LF.7 and LP.8.1.2 . It first emerged in Canada and has since spread worldwide, becoming a major driver of recent U.S. case surges.

Key characteristics:

• Belongs to the Omicron subtype

• Associated with hoarseness and scratchy throat symptoms

• Added to the European Centre for Disease Prevention and Control’s list of variants under monitoring on August 29, 2025

Nimbus

Nimbus emerged earlier in the summer of 2025 and continues to circulate alongside Stratus. Like other Omicron subvariants, Nimbus is highly transmissible but generally causes less severe illness .

Current Status

As of March 2026, Stratus (XFG) is currently the dominant circulating variant in the United States, according to CDC tracking data . Both variants, along with LP.8.1, remain under close watch by global health authorities.

Symptoms: What to Watch For

The symptoms associated with new variants in 2026 largely mirror those of earlier Omicron strains, though some patterns have emerged:

Notable patterns:

• Nimbus became known for causing “razor throat”

• Stratus appears to cause more hoarseness and voice changes

• BA.3.2 symptoms align with typical Omicron presentations

Experts note that sore throat, congestion, and hoarseness are among the most commonly reported initial symptoms with currently circulating variants .

Vaccine Protection: What We Know

Updated Vaccines for 2025–2026

The COVID-19 vaccines updated for the 2025–2026 season are designed to target the LP.8.1 variant, which was dominant when vaccine formulations were selected . While LP.8.1 has since declined, the vaccines still offer important protection.

Effectiveness Against New Variants

Clinical studies show that the updated mRNA vaccines (mRNA-1273.251 and mRNA-1283.251) elicit robust neutralizing antibodies against both the vaccine-matched variant and currently circulating variants .

However, predictive modeling indicates that BA.3.2.2 has the highest relative risk of immune escape among emerging variants following vaccination . This means the variant may be better at causing breakthrough infections in vaccinated individuals.

The Bottom Line on Vaccines

Despite reduced effectiveness against infection from highly mutated variants like BA.3.2, the vaccines remain highly effective at preventing severe disease, hospitalization, and death . This protection comes from both antibodies and T-cell responses, which continue to work against the virus even when antibody levels wane.

Who should get the updated vaccine:

• Adults aged 65 and older

• Individuals with underlying conditions that increase risk for severe COVID-19

• Anyone living with or caring for vulnerable individuals

• Those who have not received a COVID-19 vaccine in the past year

COVID-19 Treatments: Still Effective

For those who do get infected, effective treatments remain available.

Paxlovid (nirmatrelvir and ritonavir) —the antiviral medication—is expected to remain effective against all current variants because it targets a part of the virus that is not mutating rapidly . This treatment is crucial for high-risk individuals and must be started within the first five days of symptom onset.

Other treatments, including Remdesivir and Molnupiravir, are also believed to be effective against circulating variants .

Practical Steps to Stay Safe in 2026

While the public health emergency has ended, COVID-19 continues to circulate. Here are practical steps to reduce your risk:

1. Stay Up to Date on Vaccination

The single most effective step you can take is to receive the updated COVID-19 vaccine. Protection wanes over time, and updated formulations are designed to match currently circulating variants as closely as possible .

2. Consider Masking in High-Risk Settings

Wearing a high-quality, well-fitting mask (N95, KN95, or KF94) in crowded indoor spaces—such as airports, public transit, and healthcare facilities—remains an effective way to reduce your risk .

3. Test and Isolate When Symptomatic

If you develop symptoms, test yourself. Rapid antigen tests are effective at detecting currently circulating variants . If you test positive:

• Isolate from others to avoid spreading the virus

• Stay home until you are fever-free for 24 hours without medication and your symptoms are improving

• If you are in a high-risk group, contact a healthcare provider about antiviral treatment

4. Protect Vulnerable Individuals

If you are visiting elderly relatives or immunocompromised individuals, consider testing beforehand and wearing a mask during your visit. Ensuring good ventilation by opening windows can also reduce the concentration of viral particles in the air .

What Health Officials Are Saying

Sharon Nachman, MD, division chief of pediatric infectious diseases at Stony Brook Children’s Hospital, notes that while current variants are highly transmissible, they are not linked to more severe illness .

However, she cautions that this could change: “Can this change over the fall and winter? Absolutely it can. These variants have many sites of mutation from the original strains. The more people that get it, the more they pass it, the more mutations that happen” .

The CDC emphasizes the importance of continued genomic surveillance to track viral evolution and determine potential effects on public health .

Quick Reference: New COVID Variants 2026

Sources: CDC, WHO, CIDRAP

The Bottom Line

The emergence of new COVID-19 variants in 2026—particularly BA.3.2 with its significant genetic divergence—serves as a reminder that the virus continues to evolve. While these variants are highly transmissible and capable of evading some immune protection, they do not appear to cause more severe illness.

Vaccination remains the cornerstone of protection against serious outcomes. Staying up to date with the latest vaccines, practicing situational awareness with masks in high-risk settings, testing when symptomatic, and seeking early treatment if eligible are the most effective strategies for navigating the current variant landscape .

As Dr. Nachman notes, the key is to think about your own risk and the risk to those around you: “Think about who your kid is and who else is at home with you” . By taking these steps, we can continue to live our lives while managing the ongoing presence of COVID-19.

---

*This article was reviewed using information from the CDC, WHO, and peer-reviewed medical sources as of March 2026. For the latest updates, consult your local health department or healthcare provider.*